Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

umor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with NHL in 2008. Additionally, approximately 19,160 are expected to die from this disease in 2008.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

This press re
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 ... by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter ... X-ray)) & Indication (AF, VT, WPW) - Global Forecasts ... is expected to reach around ~$4.73 Billion by 2019 ... period 2014 to 2019. Browse   ...
(Date:3/27/2015)... 2015  Johnson & Johnson (NYSE: JNJ ) will ... Time) on Thursday, April 23, 2015, from the State Theatre ... Investors and other interested parties may access the live audio ... www.jnj.com and clicking on the webcast icon. ... made available a few hours after the live meeting concludes. ...
(Date:3/26/2015)... HOUSTON , March 26, 2015  The ... of a study independently conducted by the Department ... Japan have been published. ... compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant ... colorectal metastasis of the liver. ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... Flu Shot Clinics Nationwide, COLUMBIA, Md., Oct. 16 ... flu clinics hosted by Maxim Health Systems.,The company,s Web ... based on user zip codes. "We are in ... too late,to get vaccinated," said Steve Pellito, National Director ...
... Iowa, Oct. 16 Protocol Driven Healthcare,Inc. ... a partnership,with Hallmark Insights to provide fully ... of the ConXus health improvement platform. ... services,for reward points earned by participants completing ...
Cached Medicine Technology:Flu Season Is Here -- Vaccinations Are Still Plentiful 2Flu Season Is Here -- Vaccinations Are Still Plentiful 3PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs 2
(Date:3/28/2015)... March 28, 2015 With more ... the fields of osteoporosis, osteoarthritis and musculoskeletal diseases ... it may be the first time in the ... forum that the hot-button topic is an emerging ... the well-accepted scientific principles of Wolff’s law, osteogenic ...
(Date:3/28/2015)... 28, 2015 India Network visitor ... made available to all visitors who purchase the plan ... members are encouraged to purchase the insurance program as ... of proper coverage for pre-existing medical conditions. Parents and ... two medical conditions with serious consequences to their health. ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 One ... re-injury, according to research presented today at the American ... Day. The study examined the long term success of ... , “We examined survey data from 242 patients who ... author Justin P. Roe, MBBS, FRACS, from North Sydney ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Genomic medicine ... peritoneal mesothelioma, revealing, for the first time, key information ... here to read the newly posted story on ... the University of British Columbia, the British Columbia Cancer ... mapping to reveal underlying molecular alterations and mutations that ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... Persistent protein expression may explain why tumors return after ... on March 5th in the Journal of ... the most prevalent malignant brain tumor in adults, includes ... of blood vessels to the tumor. Unfortunately, in most ...
... in German . Researchers from the ... cancer cells from chemotherapy -- and they demonstrate which medication ... in the journal Natural Structural and Molecular Biology ... many cancer drugs have already been in use for decades, ...
... JACKSONVILLE, Fla. Researchers have identified a gene that causes ... necks twist involuntarily. The discovery by a team from the ... Tennessee Health Sciences Center sheds light on a movement disorder ... the Annals of Neurology . In ...
... HealthDay Reporter , FRIDAY, March 2 (HealthDay News) -- Driven ... of their own biology, women are more likely than men ... insomnia much more frequently in women, probably at least 50 ... assistant professor of neurology at the University of Texas Southwestern ...
... FRIDAY, March 2 (HealthDay News) -- Preemies face a relatively ... research suggests that the degree to which a child,s health ... child was. Those born between the 32nd and 36th ... issues than those born slightly later in the 37th or ...
... and nongovernmental organizations has published a report proposing a ... in asthma clinical research. Asthma Outcomes in Clinical Research: ... a supplement to the March 2012 issue of the ... from a meeting organized by the National Institutes of ...
Cached Medicine News:Health News:How chemotherapy becomes more effective 2Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 2Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 3Health News:For Sleep Struggles, Women Urged to Alter Routines 2Health News:For Sleep Struggles, Women Urged to Alter Routines 3Health News:For Sleep Struggles, Women Urged to Alter Routines 4Health News:Timing of Preemie Birth May Be Key to Kids' Health Later 2Health News:Standardized outcome measures proposed for asthma clinical research 2
... The Medtronic InSync II Marquis ... and ICD therapy. Cardiac resynchronization benefits ... adapt pacing outputs to unique patient ... monitoring functions that help physicians manage ...
... housing. MRI-compatible. Requires a guide sphere ... a standard 1.0 - 1.5 cm burr ... assembly with a white collar. MRI-compatible. ... Sterile; single-use only Guide sphere assembly with ...
... PCL Guides were developed to reproducibly and ... arthroscopic double bundle PCL reconstruction. The guides ... posteromedial femoral tunnel sockets drilled endoscopically from ... placement a guide can be used either ...
... new standard in the field of hammertoe implants ... of medical grade silicone, these durable and lasting ... level of flexibility while maintaining correct toe length ... varying stiffnesses. Lengths are determined by the surgeon ...
Medicine Products: